Clinical Evaluation of Fenfuro (Fenugreek Seed Extract) in Type-2 Diabetic Subjects: an add-on Study

Open Labeled, Interventional, Two Armed, Single Centric Study to Assess the Efficacy of Fenfuro (Fenugreek Seed Extract) in Type-2 Diabetic Subjects: an add-on Study

This study is an open label, two armed trial evaluating the safety and efficacy of Fenfuro capsule twice daily for 90 days in 100 patients with type 2 diabetes that will be conducted in single center in India. The primary outcome measures will be the determination of decrease in plasma glucose levels from baseline to last visit. The secondary outcome will be the determination of safety of Fenfuro capsule in type 2 diabetic subjects.

Study Overview

• Status: Completed
• Conditions: Type 2 Diabetes Mellitus
• Intervention / Treatment: Drug: Fenfuro

Detailed Description

Diabetes mellitus, involving rise in blood sugar levels, has shown to be a highly prevalent disease. Treatments and treatment regimens include combinations of oral anti-diabetic drugs (OADs), anti-hypertensive medications and anti-dyslipidemic agents, but these have been less than successful in managing their respective disease targets with clinical goals. Now-a-days, the treatment strategies for diabetes mellitus type 2 which are opted by general population include natural supplements. This choice is based upon the involvement of very less side effects along with high effectiveness of the natural supplements as compared to the synthetic medications. One of those natural supplements is fenugreek seeds extract i.e. Fenfuro which has been used as a nutraceutical in the present study for the management of type 2 diabetes mellitus.

Fenugreek has been extensively used as a source of anti-diabetic compounds from long time. Thus, Fenfuro, prepared from fenugreek seeds extract, is supposed to have anti-diabetic properties as well. Previous studies on fenugreek seeds extract have shown effective and safe anti-diabetic and anti-hyperlipidemic properties of it. It has shown to decrease blood glucose levels as well as lipid profile of the diabetic patients.

In this proposed study, Fenugreek seed extract will be used as an add-on to the existing therapy in patients with type-2 diabetes. The efficacy and safety of the extract will be evaluated using standard methodology.

• Study Type: Interventional
• Enrollment (Actual): 104
• Phase: Phase 4

Contacts and Locations

Study Locations

• India
  • Punjab
    • Rajpura, Punjab, India, 140601
      • Gian Sagar Medical College & Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Agrees to written as well as audio-visual informed consent.
• Patients of either sex.
• Aged 18-65 years.
• Fasting plasma glucose level <180 mg/dL.
• HbA1c level more than 7.5%.
• Not receiving any steroids.
• Patient on anti-diabetic therapy.

Exclusion Criteria:

• Uncooperative Subjects.
• Diabetes other than type-2 diabetes mellitus.
• Evidence of renal & liver disease.
• History of any hemoglobinopathy that may affect determination of HbA1c.
• Lactating and Pregnant or planning to conceive females.
• Physically/ mentally unwell as certified by physician-in-charge.
• Participation in any other clinical trial with in the last 30 days.
• Subjects with allergy to investigational product.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: SUPPORTIVE_CARE
• Allocation: NON_RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Group A; Fenfuro 500 mg capsule by mouth, BD (two times a day), till next follow-up	Drug: Fenfuro; Other Names: Fenugreek seed extract
NO_INTERVENTION: Group B; Investigational product is not being administered to this arm. This arm will regularly be observed on follow-up and laboratory investigations will be performed.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change in Fasting Blood Sugar	On completion of treatment (i.e.12 weeks) as compared to baseline
Change in Postprandial sugar	On completion of treatment (i.e.12 weeks) as compared to baseline

Secondary Outcome Measures

Outcome Measure	Time Frame
Change in HbA1c levels	On completion of treatment (i.e.12 weeks) as compared to baseline
SGPT,SGOT,ALP,Creatinine,TLC,DLC & Hb	On completion of treatment (i.e.12 weeks) as compared to baseline

Collaborators and Investigators

• Sponsor: Chemical Resources

Study record dates

Study Major Dates

• Study Start (ACTUAL): December 14, 2015
• Primary Completion (ACTUAL): October 1, 2017
• Study Completion (ACTUAL): October 1, 2017

Study Registration Dates

• First Submitted: November 1, 2016
• First Submitted That Met QC Criteria: February 22, 2017
• First Posted (ACTUAL): February 28, 2017

Study Record Updates

• Last Update Posted (ACTUAL): January 31, 2018
• Last Update Submitted That Met QC Criteria: January 29, 2018
• Last Verified: June 1, 2017

More Information

Terms related to this study

• Keywords: FBS,HbA1C, PPBS
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2
• Other Study ID Numbers: CR-FEN/PREDIA/02/15

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No